Investigating mediated effects of fear of COVID-19 and COVID-19 misunderstanding in the association between problematic social media use, psychological distress, and insomnia

Introduction: Due to the serious situation of the novel coronavirus disease 2019 (COVID-19) worldwide, many countries have implemented policies to minimize the spread of COVID-19 infection. However, some of these policies prevent people from physical contact. Consequently, many individuals may rely on social media to obtain information concerning COVID-19. Unfortunately, social media use (especially problematic social media use) may give rise to psychological distress. Therefore, this study thus examined potential psychopathology to explain the association between problematic social media use, psychological distress, and insomnia. Methods: Utilizing an online survey, a sample of Iranian young adults (n = 1078 with 628 males; mean age = 26.24 years [SD ± 7.41]) completed questions and psychometric scales concerning psychological distress, insomnia, problematic social media use, fear of COVID-19, and COVID-19 misunderstanding. Results: Problematic social media use was significantly associated with psychological distress both directly and indirectly. The indirect effects were through fear of COVID-19 (unstandardized coefficient [B] = 0.177; Bootstrapping SE = 0.026) and COVID-19 misunderstanding (B = 0.060; Bootstrapping SE = 0.014). Problematic social media use was significantly associated with insomnia both directly and indirectly. The indirect effect was through fear of COVID-19 (B = 0.062; Bootstrapping SE = 0.019) but not COVID-19 misunderstanding (B = 0.012; Bootstrapping SE = 0.014). Discussion/conclusion: Due to the pressure of the COVID-19 outbreak, individuals are highly likely to develop psychological distress and insomnia. Apart from developing appropriate health policies to minimize the spread of COVID-19 infection, healthcare providers should design appropriate online campaigns to eliminate people's fear of COVID-19 and to diminish misunderstanding concerning COVID-19

Safety of COVID-19 vaccines administered in the EU: Should we be concerned?

The COVID-19 pandemic has had an unprecedented and devastating impact on public health, society and economics around the world. As a result, the development of vaccines to protect individuals from symptomatic COVID-19 infections has represented the only feasible health tool to combat the spread of the disease. However, at the same time the development and regulatory assessment of different vaccines has challenged pharmaceutical industries and regulatory agencies as this process has occurred in the shorter time ever though. So far, two mRNA and two adenovirus-vectored vaccines have received a conditional marketing authorisation in the EU and other countries. This review summarized and discusses the assessment reports of the European Medicine Agency (EMA) concerning the safety of the 3 vaccines currently used in the EU (Pfizer, Moderna and Astra-Zeneca). A particular focus has been paid to safety information from pre-clinical (animal) and clinical (phase 3 trials) studies. Overall, the most frequent adverse effects reported after the administration of these vaccines consisted of local reactions at the injection site (sore arm and erythema) followed by non-specific systemic effects (myalgia, chills, fatigue, headache, and fever), which occurred soon after vaccination and resolved shortly. Rare cases of vaccine-induced immune thrombotic thrombocytopenia have been reported for Vaxzevria. Data on long-term studies, interaction with other vaccines, use in pregnancy/breast-feeding, use in immunocompromised subjects, and in subjects with comorbidities, autoimmune or inflammatory disorders are still missing for these vaccines. Therefore, careful follow-up and surveillance studies for continued vaccine safety monitoring will be needed to ascertain the potential risks of such adverse events or diseases. In conclusion, the benefits and risks of current COVID-19 vaccines must be weighed against the real possibility of contract the disease and develop complications and long-term sequels; all this on the basis of the available scientific evidence and in the absence of unmotivated biases